Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting

OnabotulinumtoxinA was approved for treatment of chronic migraine (CM) after publication of Phase 3 Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials. However, the PREEMPT trials lasted only up to 1 year. The main aim of our retrospective study was to evaluate whether a prolonged tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Santoro, Antonio, Fontana, Andrea, Miscio, Anna M., Zarrelli, Michele M., Copetti, Massimiliano, Leone, Maurizio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605581/
https://www.ncbi.nlm.nih.gov/pubmed/28726049
http://dx.doi.org/10.1007/s10072-017-3054-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5605581/
https://www.ncbi.nlm.nih.gov/pubmed/28726049
http://dx.doi.org/10.1007/s10072-017-3054-y

Ejemplares similares